Study Title: A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination with Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI21-500
 

• Open to Accrual at:
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
• Learn more:
  • clinicaltrials.gov: NCT05624918

Study Contact: studies@hoosiercancer.org; (317) 921-2050.